For clinic owners asking do GLP-1 clinics need a good faith exam, the practical answer is generally yes. Before prescribing semaglutide, tirzepatide, or another prescription weight-loss medication, an appropriately licensed provider usually needs to evaluate the patient, decide whether treatment is suitable, and document that decision.
The exact language differs by state. Some states use the term “good faith exam,” while others address the same step through prescribing, telehealth, scope-of-practice, or practitioner-patient relationship rules. What matters is whether a patient-specific evaluation occurs before prescribing.
Do GLP-1 Clinics Need a Good Faith Exam Before Prescribing?
Most GLP-1 clinics should expect a patient-specific evaluation before prescribing. The provider should review relevant information, assess suitability, and record the basis for the decision.
A state may not require an encounter under that exact name. Prescribing rules may instead require an appropriate professional relationship, sufficient clinical information, and independent medical judgment before a prescription is issued.
A clinic should be able to answer four questions:
- Who evaluated the patient?
- What information did the provider review?
- What clinical decision was made?
- Where was that decision documented?
If the chart contains only a questionnaire or automated approval, it may not show the clinical judgment required for prescribing. This is why the answer to do GLP-1 clinics need a good faith exam depends partly on state terminology but consistently returns to the quality and timing of the clinical review.
What Does the Evaluation Establish?
A GLP-1 good faith exam creates the clinical basis for prescribing. It shows that a qualified provider reviewed the patient’s health information and decided whether treatment should proceed, change, pause, or be declined.
Consent documents that the patient understands the proposed treatment and accepts its risks. The evaluation determines whether treatment is medically appropriate.
Intake also serves a different role. The provider must interpret the information, ask follow-up questions when needed, and document an individualized decision. What Is a Good Faith Exam? explains the distinction.
Why GLP-1 Screening Requires a Treatment-Specific Review
A Botox or filler evaluation focuses on suitability for a defined procedure. GLP-1 care involves a systemic prescription medication that may require dose selection, titration, side-effect monitoring, and follow-up over time.
That difference changes what the provider needs to review. A cosmetic intake may focus on allergies, previous injections, pregnancy, and procedural history. A good faith exam for weight loss medications may also need to address current medications, diabetes treatment, gastrointestinal disease, pancreatitis history, gallbladder disease, kidney concerns, pregnancy status, and product-specific contraindications.
The current FDA prescribing information for Wegovy and FDA prescribing information for Zepbound identify medication-specific contraindications, warnings, adverse effects, and monitoring considerations. The provider should review the exact product labeling rather than rely on a generic injectable checklist.
This is the central GLP-1 compliance issue. The chart should show why the provider considered the prescription appropriate for that patient, not merely that the patient requested treatment.
What Should the Provider Review?
The review depends on the medication, patient history, and clinician’s judgment. It may include:
- Medical and surgical history
- Current medications, supplements, and allergies
- Previous weight-loss medications and treatment response
- Diabetes history and glucose-lowering therapy
- Personal or family history relevant to thyroid warnings
- History of pancreatitis or gallbladder disease
- Severe gastrointestinal symptoms or gastroparesis
- Kidney disease, dehydration risk, or relevant laboratory findings
- Pregnancy status and reproductive considerations
- Proposed starting dose, titration, and follow-up plan
The provider may approve, modify, delay, or decline treatment, request more information, or require an in-person assessment. The process should not function as automatic clearance.
Where Should the Exam Fit Into the Workflow?
The evaluation belongs between patient intake and prescription authorization.
1. Collect treatment-specific information
The clinic gathers medical history, current medications, allergies, relevant symptoms, and prior treatment details.
2. Route the case to an eligible provider
The provider must be authorized to evaluate the patient under the rules that apply where the patient is located.
3. Complete the clinical review
The provider interprets the information, asks follow-up questions, and considers medication-specific risks.
4. Document the decision
The chart records the provider’s findings and whether treatment was approved, modified, delayed, declined, or held pending further information.
5. Begin prescribing and follow-up
The prescription process begins only after clinical authorization. Follow-up then addresses response, dosing, adverse effects, and changes in health status.
This separates commercial onboarding from medical decision-making. Payment, enrollment, or pharmacy coordination does not prove clinical clearance.
Can the Evaluation Be Completed Through Telehealth?
A remote encounter may be appropriate when the provider is authorized and the visit satisfies the patient’s state rules.
A telehealth GFE for GLP-1 still requires meaningful provider review, an individualized decision, and complete documentation. Telehealth changes the encounter format. It does not remove the need for clinical judgment.
Multi-state clinics should verify patient location, provider authority, permitted encounter methods, and documentation requirements. One workflow may not work unchanged in every state.
How Often Should Patients Be Reassessed?
There is no single national reassessment interval. Timing depends on state rules, the medication, the treatment plan, patient response, and provider judgment.
Reassessment may be appropriate after a dose change, a new adverse effect, a new diagnosis, a medication change, a treatment interruption, or another meaningful change in health status. The original evaluation should not be treated as permanent authorization for every future refill.
Common Workflow Mistakes
Clinic owners researching GLP-1 med spa requirements often discover that the main risk is not a missing form but a weak clinical handoff. Common mistakes include:
- Reusing a cosmetic intake without medication-specific questions
- Treating enrollment or payment as clinical approval
- Allowing non-prescribing staff to infer the provider’s decision
- Using the same telehealth method in every state
- Recording “approved” without documenting supporting findings
- Assuming one evaluation covers every future refill
- Failing to reassess after meaningful health or dosing changes
- Treating the exam as proof that a compounded product is safe or properly sourced
Compounded medications create a separate issue. A clinical evaluation assesses the patient, not the quality of the drug or pharmacy. The FDA states that compounded drugs are not FDA-approved and has published specific concerns about unapproved GLP-1 products used for weight loss. Clinics should evaluate pharmacy legitimacy and product sourcing separately from patient suitability.
Conclusion
For clinic owners asking do GLP-1 clinics need a good faith exam, the most accurate answer is that a documented, patient-specific clinical evaluation is generally expected before prescribing, while the exact requirements vary by state.
The evaluation should remain focused on the patient, the medication, and the provider’s decision. It should not become a generic formality added to a sales workflow. Clinics that need a clearer operational model can review the GoodFaithExams GLP-1 clinic resource after confirming the rules that apply to their providers and patient locations.
Frequently Asked Questions
What Is a Good Faith Exam for a GLP-1 Clinic?
It is a patient-specific clinical evaluation completed before prescribing. A qualified provider reviews relevant health information, assesses suitability, and documents whether treatment should proceed, change, or stop.
Do You Need a GFE for Semaglutide/Tirzepatide?
Generally, a documented evaluation is expected before either medication is prescribed. The provider type, encounter method, documentation rules, and follow-up obligations depend on the patient’s state.
Who Needs the Evaluation?
Patients entering a clinic-based GLP-1 program may need evaluation before prescription authorization. The requirement depends on the treatment model, provider arrangement, patient location, and applicable state rules.
Who Can Perform the Evaluation?
Provider eligibility depends on state law and professional scope. A physician, nurse practitioner, or physician assistant may qualify, depending on the jurisdiction, licensure status, and prescribing arrangement.
When Should the Evaluation Occur?
The evaluation should occur before the prescription is issued. Completing it afterward does not establish the clinical basis that should have preceded prescribing or treatment authorization.
Is a Patient Intake Form Enough?
No. Intake collects patient-reported information, but it does not show that a licensed provider reviewed the case, assessed medication-specific risks, and made an individualized decision.
Can the Evaluation Be Completed Online?
It may be completed remotely when state rules permit. The provider must still conduct an adequate review, interact with the patient as required, and document the decision. A form-only workflow may be insufficient.
Does Completing the Evaluation Guarantee Approval?
No. The provider may approve, modify, delay, or decline treatment, request more information, or require an in-person assessment based on the patient-specific review.
How Often Should the Evaluation Be Repeated?
There is no universal interval. Dose changes, adverse effects, new diagnoses, medication changes, treatment interruptions, or state rules may trigger reassessment.
Does the Evaluation Cover Every Future Refill?
Not automatically. Continued prescribing depends on the patient’s response, current health information, treatment plan, and any follow-up required by the provider or state.
Does the Evaluation Verify Compounded GLP-1 Medication?
No. It evaluates patient suitability. Pharmacy legitimacy, product quality, sourcing, and compounding practices require a separate review and are not validated by the exam.
What Should a Clinic Review Before Launching GLP-1 Services?
The clinic should review provider eligibility, patient-location rules, treatment-specific intake, documentation, prescribing procedures, pharmacy coordination, follow-up responsibilities, and current FDA product information. It should also define who handles adverse-event escalation and medication changes.
